

Cebiotex appoints Joan Torrejon as its new CEO

- **Cebiotex begins a new stage with a change in its executive management in order to take a more strategic step towards business**
- **The current CEO, Joan Bertran, will take over the position of Chairman of the Board of Directors**

Barcelona, 27 October 2025 – **Cebiotex**, an innovative biotechnology start-up, spin-off of the Polytechnic University of Catalonia (UPC) and SJD Barcelona Children's Hospital (HSJD), specialising in controlled-release membranes for the treatment of cancer in both adults and children, announces a new strategic step by appointing **Joan Torrejon Mir** as its new CEO.

This decision marks the beginning of a new phase in the growth of the company that has been constantly developing since its foundation in 2012. **Joan Bertran**, co-founder and CEO until now, will hold the position of Chairman of the Board of Directors. Bertran has led an accelerated growth of Cebiotex and has been able to accompany himself with the best team of professionals since the beginning. The start-up, which was born with the mission of providing innovative solutions in pediatric oncological surgery, begins this new era under the command of Joan Torrejon in order to continue growing, focusing on the business, and above all, maintaining the mission and objective of expanding its technological platform towards new therapeutic areas.

Joan Torrejon Mir, a renowned executive in Catalonia, and a biologist by training, has more than 40 years of experience in the pharmaceutical industry where he has worked in leading companies in the sector such as UCB, Biogen, Chiesi, Esteve and Almirall. Torrejon provides a strategic and business vision that is essential for this new phase of expansion and growth that Cebiotex is experiencing.

As Torrejón says, *"it is an honour to take over from **Joan Bertran Llavina**. Cebiotex is a unique project with a clear mission in which we have a technological platform and a pipeline with the potential to transform the management and treatment of tumours such as pancreatic cancer, sarcoma, or glioblastoma. In this new phase, the priority is to accelerate and be able to bring to market innovative solutions that respond to medical needs that have not yet been met, improving the life expectancy and quality of life of cancer patients"*.

As Bertran, founder and soul of the start-up, concludes, *"Cebiotex was born from a very hard loss: that of Sara, a 6-year-old girl who fought for 4 years against neuroblastoma. This impotence led me to dedicate myself to researching and developing biomaterials that could provide real solutions to pediatric oncology. After four years of working with researchers from the UPC and SJD Barcelona Children's Hospital, in 2012 we set up the company and, in 2015, after closing the 1st Round of Funding, we started its activity. Today, I am proud to see how much we have grown and I am convinced that this change in management will allow us to take another step forward in our clinical and regulatory development to bring our innovative solutions closer to the patients who need them most"*.



About Cebiotex

Cebiotex is a Catalan biotechnology start-up founded with the mission of developing drug-controlled release membranes capable of releasing drugs locally and sustainably over time, providing innovative solutions in adult and pediatric cancer surgery. The company has products in preclinical and clinical phase II development for different oncological indications, including pancreatic cancer, sarcoma, neuroblastoma and glioblastoma, and is exploring new applications based on its proprietary technology platform.

More information:

www.cebiotex.com

[LinkedIn](#)